BPC
Body Protection Compound-157, a pentadecapeptide derived from human gastric juice that has been studied in animal models of tissue injury.
Regulatory status (as of Sept 2026)
Not FDA-approved. Removed from 503A Category 2 on April 15, 2026. PCAC recommended for the 503A Bulks List (advisory); awaiting FDA rulemaking; not lawfully compoundable under 503A as of Sept 17, 2026. PCAC vote: 8–6–1 (yes–no–abstain), July 23, 2026.
See the FDA peptide regulatory tracker · Read our July 27, 2026 dispatch on the FDA PCAC peptide vote2 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
BPC-157 is a compound studied only in animals and lab experiments so far. Body Protection Compound-157, a pentadecapeptide derived from human gastric juice that has been studied in animal models of tissue injury.
| Half-life | Under 30 min (rats and beagle dogs, IV and IM) detailsElimination t1/2 < 30 min (rats and beagle dogs, IV and IM); IM bioavailability ~14-19% rats, 45-51% dogs |
|---|---|
| How it's given in studies | Subcutaneous injection |
| Research stage | Preclinical (animal) |
| Dosing | Published research: No published human dosing detailsRodent studies dose per kg (commonly µg/kg or ng/kg, i.p. or oral); He et al. 2022 used single and repeated IM doses in rats/dogs. No human dose-finding study in PubMed.Community-reportedCommunity-reported: 250–500 mcg, subcutaneous injection |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: Animal and cell studies suggest it may support blood-vessel growth and healing signals; this has not been tested in controlled human trials. Proposed mechanisms, from preclinical (animal and cell) studies, not tested in controlled human trials: angiogenesis, endothelial protection, increased growth-factor expression (including VEGF and EGF), and interaction with the nitric oxide and dopamine systems. A 2026 orthopaedic review notes that clinical trials are lacking (Rahman 2026).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedSome users report running BPC-157 at 250–500 mcg (subcutaneous injection). This is not a recommendation.
Side effects reported in studies are listed separately below.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
BPC-157 arginate is an arginine salt form of BPC-157, marketed as more stable than the acetate form. No published studies of the arginate form were found: there are no published comparative stability, pharmacokinetic or safety data for this salt, and salt forms are not separately reviewed by PCAC.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| BPC-157 | Elimination t1/2 < 30 min (rats and beagle dogs, IV and IM); IM bioavailability ~14-19% rats, 45-51% dogs | Subcutaneous injection | Preclinical (animal) |
| ARA-290 (Cibinetide) | No published PK data found | Subcutaneous injection, Intravenous | Phase 2 |
| Copper Peptide AHK-Cu | Topical (not systemically relevant) | Topical | In vitro only |
| GHK-Cu | No published PK data found | Subcutaneous or topical | Cosmetic/topical |
| Pentapeptide-18 | Unknown | Topical | Cosmetic/topical |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Healing category. View All Healing Peptides
Cognitive
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.